Mounjaro dose splitting chart: what the clinical guidance says

What the licensed schedule tells us, and why it is structured this way

The SURMOUNT-1 trial, published in the New England Journal of Medicine, studied tirzepatide at 5, 10 and 15 mg given as a single weekly subcutaneous injection. Across 72 weeks, participants at the highest dose achieved average body-weight reductions of around 20–21%. That result was produced by a carefully calibrated once-weekly protocol, titrated upward in 4-week steps to allow tolerability, not split across multiple smaller injections. The NHS medicines page for tirzepatide reflects the same structure: one injection, once a week, at the strength your prescriber has set.

The reason the schedule is built this way relates to how tirzepatide behaves in the body. Its half-life is roughly five days, which is precisely why weekly dosing produces a steady blood-level curve. Splitting that dose (injecting half on Monday and half on Thursday, for example) would not recreate the same curve; it would produce two smaller peaks and a different trough, in a pattern that has never been tested for efficacy or safety. There is no published evidence that splitting a tirzepatide dose preserves the weight-loss effect or reduces side effects compared with the licensed approach.

If you are curious about how doses are structured across the full titration schedule, the Mounjaro dose chart on this site sets out the six licensed strengths and the typical titration steps in plain terms.

The KwikPen mechanism and why splitting is a practical problem, not just a regulatory one

Some people searching for a dose splitting chart are thinking practically: the pen has multiple doses in it, so can you just use less per injection? The answer is no, for a mechanical reason. Each KwikPen contains four weekly actuations at a fixed pre-set volume. Press the button once and the pen delivers one complete dose, there is no dial you can turn to deliver half. The device is not calibrated for partial actuation, and the dose per depression is fixed at manufacture. Attempting to interrupt an injection partway through is not a reliable or sterile approach.

This is different from some insulin pens, where a dial allows any number of units. Mounjaro's KwikPen is a fixed-dose auto-injector. That distinction matters because instructions for splitting other injectable medicines should never be carried across to tirzepatide, the delivery systems are not equivalent. Storage conditions compound the issue: a pen that has been partially used in an unintended way introduces contamination and temperature-exposure questions that the SmPC does not address, because the scenario is outside the licensed use. For step-by-step technique guidance that stays within the licensed method, the guide to splitting Mounjaro doses covers what the SmPC actually permits and what it does not.

What to do if the dose feels too strong or side effects are troublesome

The most common reason people look for a dose splitting chart is that their current dose is causing nausea, fatigue or gastrointestinal discomfort, and they want to reduce exposure without missing a week entirely. That instinct is understandable. The licensed answer to it is a prescriber conversation, not self-adjustment.

NICE's technology appraisal of tirzepatide (TA1026) notes that treatment should proceed at the highest tolerated dose, the word tolerated is doing real work there. If 5 mg is causing significant side effects, staying at 2.5 mg for longer than the standard four-week step is a legitimate clinical decision. Delaying titration is within the licensed framework; splitting a single dose is not. Some patients also ask whether taking a half dose twice a week might offer a gentler experience, a question that page addresses directly alongside the evidence for why that approach falls outside the licensed schedule. The 5 mg dose guide covers how that step is typically managed and what questions are worth raising at your next review.

Timing injections with food, staying well hydrated, and giving the body time to adjust are all approaches supported by clinical experience. Our clinical team fields questions about tolerability regularly, it is one of the most common concerns in early treatment. The answer is rarely dose splitting; it is nearly always a titration conversation. If you have questions about your own schedule, the free consultation is the right place to raise them with a prescriber who can read your full picture.

Cost, availability and why dose splitting is sometimes framed as a workaround

There is another reason this query surfaces: cost. Some people reason that splitting a higher-strength pen across two weeks reduces the monthly spend. The context around Mounjaro pricing in the UK is relevant here, Eli Lilly raised list prices significantly from September 2025, and private market prices have followed. That pressure is real, and we do not dismiss it.

The clinical answer, though, is that dose splitting to make a pen last longer is not a cost-saving measure that a prescriber can endorse. It moves the patient outside the licensed schedule without evidence that the reduced exposure maintains efficacy, and it introduces the practical and sterile-use issues described above. A pen stored past its use-by window or re-accessed multiple times outside the intended four-injection sequence creates risks the manufacturer has not evaluated.

If cost is the driver, a straightforward conversation with a prescriber about whether your current dose is the right one (or whether there is a lower licensed strength that suits you at this stage) is a more defensible path. The Mounjaro dosage chart sets out all six strengths and what the evidence says about each. Understanding where you sit on that schedule is a better starting point than trying to extend a pen beyond its intended use.